PF-06952229 是 TGFβRI 的选择性抑制剂。 PF-06952229 可用于治疗实体瘤，特别是转移性乳腺癌的研究。

PF-06952229 is a selective inhibitor of TGFβRI. PF-06952229 can be used in studies about the treatment of solid tumors, specifically metastatic breast cancer.

In MCF-7 ER+ HER2-xenograft breast cancer tumor model, PF-06952229 (30 mg/kg; gavage) combines with Palbociclib results in an improved inhibition of pSMAD2 and a significant increase in survival[1].

1801333-55-0

C23H24ClFN4O3

458.91

PF06952229

DMSO:40 mg/mL (87.2 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years